Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: THR004
MIFTS: 54

Thrombocytosis

Categories: Blood diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Thrombocytosis

About this section

MalaCards integrated aliases for Thrombocytosis:

Name: Thrombocytosis 12 76 29 55 44 15 73
Thrombocythaemia 12

Classifications:

MalaCards categories:
Anatomical: Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2228
MeSH 44 D013922
NCIt 50 C35530
UMLS 73 C0836924
Sources

Summaries for Thrombocytosis

About this section
Disease Ontology : 12 A blood platelet disease that is characterized by the presence of high platelet counts in the blood.

MalaCards based summary : Thrombocytosis, also known as thrombocythaemia, is related to thrombocythemia 1 and myeloproliferative neoplasm. An important gene associated with Thrombocytosis is JAK2 (Janus Kinase 2), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Anagrelide and Hydroxyurea have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are hematopoietic system and cardiovascular system

Wikipedia : 76 Thrombocythemia (also thrombocytosis) is the presence of high platelet (thrombocyte) counts in the... more...

Sources

Related Diseases for Thrombocytosis

About this section

Diseases related to Thrombocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 361)
# Related Disease Score Top Affiliating Genes
1 thrombocythemia 1 33.6 MPL THPO
2 myeloproliferative neoplasm 30.8 JAK2 MPL TET2
3 splenomegaly 30.6 EPO JAK2 MPL
4 polycythemia vera 30.5 EPO IL3 JAK2 MPL SELP TET2
5 refractory anemia 30.2 EPO IL3 JAK2 MPL TET2
6 iron deficiency anemia 30.2 CRP EPO IL6 THPO
7 poems syndrome 30.0 EPO IL6
8 myeloid leukemia 29.8 CSF2 IL3 JAK2 TET2
9 myelodysplastic myeloproliferative cancer 29.7 CSF2 JAK2 TET2
10 peritonitis 29.6 CRP F2 IL6
11 deficiency anemia 29.5 CRP EPO IL3 IL6 THPO
12 polycythemia 29.4 EPO IL3 JAK2 MPL TET2 THPO
13 thrombocytopenia 29.4 F3 IL11 MPL THPO
14 myelofibrosis 29.4 EPO IL3 JAK2 MPL TET2 THPO
15 central retinal vein occlusion 29.3 F2 IL6 SERPINC1
16 retinal vein occlusion 29.3 F2 IL6 SERPINC1
17 burns 29.2 CSF2 SERPINC1
18 eosinophilic gastroenteritis 29.2 CSF2 IL3
19 thrombocytopenic purpura, autoimmune 29.1 IL11 MPL SELP THPO
20 myeloma, multiple 28.7 CRP CSF2 EPO IL6
21 leukemia, acute myeloid 28.7 CSF2 IL3 JAK2 MPL TET2 THPO
22 portal vein thrombosis 28.7 F2 JAK2 SELP SERPINC1
23 pancytopenia 28.5 CSF2 EPO IL3 MPL THPO
24 monocytic leukemia 28.5 CSF2 F3 IL6
25 von willebrand's disease 28.5 F2 F3 SELP
26 essential thrombocythemia 28.5 EPO F2 F3 IL11 IL3 JAK2
27 leukemia, chronic myeloid 28.4 CSF2 EPO IL3 JAK2 MPL THPO
28 budd-chiari syndrome 28.2 F2 F3 JAK2 SERPINC1
29 thrombophilia due to thrombin defect 28.1 F2 F3 SERPINC1
30 heparin-induced thrombocytopenia 28.1 F3 SELP SERPINC1
31 pulmonary embolism 27.9 CRP F2 F3 SERPINC1
32 thrombosis 27.9 F2 F3 JAK2 SELP SERPINC1
33 acute myocardial infarction 27.9 CRP F3 SELP SERPINC1
34 coronary artery anomaly 27.8 CRP F3 IL6 SELP
35 thrombophilia 27.7 F2 F3 JAK2 SERPINC1
36 myelodysplastic syndrome 27.7 CSF2 EPO IL11 IL3 JAK2 MPL
37 purpura 27.1 CRP F2 F3 MPL SERPINC1 THPO
38 hemorrhagic disease 26.9 F2 F3 JAK2 MPL SERPINC1 THPO
39 myocardial infarction 26.9 CRP F2 F3 IL6 SELP SERPINC1
40 heart disease 26.8 CRP F2 F3 IL6 SERPINC1
41 arteries, anomalies of 26.0 CRP F2 F3 IL6 SELP SERPINC1
42 vascular disease 26.0 CRP F2 F3 IL6 SELP SERPINC1
43 erythromelalgia 11.2
44 thrombocythemia 3 11.0
45 thrombocythemia with distal limb defects 11.0
46 thrombocythemia, x-linked 10.9
47 thrombocythemia 2 10.9
48 thrombocytopenia 3 10.9 MPL THPO
49 dyskeratosis congenita, autosomal dominant 6 10.8 MPL THPO
50 vibrio vulnificus infection 10.8 EPO IL6

Graphical network of the top 20 diseases related to Thrombocytosis:



Diseases related to Thrombocytosis
Sources

Symptoms & Phenotypes for Thrombocytosis

About this section

MGI Mouse Phenotypes related to Thrombocytosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.14 F3 CSF2 IL6 EPO JAK2 F2
2 cardiovascular system MP:0005385 10.11 CRP F3 CSF2 IL6 EPO F2
3 homeostasis/metabolism MP:0005376 10.11 CRP F3 CSF2 IL6 EPO JAK2
4 immune system MP:0005387 10.1 F3 CRP CSF2 IL6 EPO JAK2
5 embryo MP:0005380 9.98 F3 CSF2 EPO JAK2 F2 MPL
6 integument MP:0010771 9.8 F3 CSF2 IL6 EPO JAK2 F2
7 mortality/aging MP:0010768 9.65 F3 CSF2 IL6 EPO JAK2 F2
8 liver/biliary system MP:0005370 9.63 IL6 EPO JAK2 SELP SERPINC1 TET2
9 respiratory system MP:0005388 9.1 F2 F3 CSF2 IL6 EPO SELP
Sources

Drugs & Therapeutics for Thrombocytosis

About this section

Drugs for Thrombocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 268)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Anagrelide Approved Phase 4,Phase 3,Phase 2 68475-42-3 2182
2
Hydroxyurea Approved Phase 4,Phase 3,Phase 2,Not Applicable 127-07-1 3657
3
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
4
Zinc Approved, Investigational Phase 4 7440-66-6 23994
5 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2
6
Lactitol Investigational Phase 4,Phase 2,Phase 3 585-86-4 3871
7 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
8 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
9 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
10
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
11
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
12
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 55-98-1 2478
13
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
14
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
15
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
16
Aspirin Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-78-2 2244
17
Peginterferon alfa-2a Approved, Investigational Phase 3,Phase 2,Phase 1 198153-51-4 5360545
18
Peginterferon alfa-2b Approved Phase 3 99210-65-8, 215647-85-1
19
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
20
Dalteparin Approved Phase 3 9005-49-6
21
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
22
Ondansetron Approved Phase 3,Phase 1,Phase 2,Not Applicable 99614-02-5 4595
23
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
24
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
25
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
26
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
27
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Not Applicable 93-14-1 3516
28
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
29
Ribavirin Approved Phase 3 36791-04-5 37542
30 Pomalidomide Approved Phase 3,Phase 1,Phase 2 19171-19-8
31
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
32
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1 148-82-3 4053 460612
33
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
34
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
35
Danazol Approved Phase 3,Phase 2 17230-88-5 28417
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
37
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
38
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
39
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
40 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
41 Analgesics Phase 3,Phase 2,Phase 1,Not Applicable
42 Anesthetics Phase 3
43 Anesthetics, Dissociative Phase 3
44 Anesthetics, General Phase 3
45 Anesthetics, Intravenous Phase 3
46 Central Nervous System Depressants Phase 3,Phase 1,Phase 2,Not Applicable
47 Excitatory Amino Acid Antagonists Phase 3
48 Excitatory Amino Acids Phase 3
49 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
50 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 268)
# Name Status NCT ID Phase Drugs
1 A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients Completed NCT00202644 Phase 4 Anagrelide;Hydroxyurea
2 Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4 INC424
3 Anagre Cap. in Patients With High-Risk Essential Thrombocythemia Recruiting NCT03232177 Phase 4 Anagre Cap.
4 CINC424A2X01B Rollover Protocol Recruiting NCT02386800 Phase 4 Ruxolitinib
5 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
6 Anagrelide Retard in Essential Thrombocythemia Completed NCT02076815 Phase 3 Anagrelide retard;Thromboreductin
7 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Completed NCT01259856 Phase 3 PEGASYS;Hydroxyurea;Aspirin
8 Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia Completed NCT01214915 Phase 3 Anagrelide Hydrochloride
9 Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia Completed NCT01230775 Phase 3 Anagrelide retard;Placebo
10 Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia Completed NCT01065038 Phase 3 Anagrelide;Hydroxyurea
11 Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia Completed NCT01467661 Phase 3 SPD422 (anagrelide hydrochloride)
12 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Completed NCT02087059 Phase 3 Ruxolitinib
13 INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. Completed NCT01493414 Phase 3 INC424
14 COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Completed NCT00952289 Phase 3 Ruxolitinib;Placebo
15 Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial Completed NCT00934544 Phase 3 INC424/INCB018424;Best Available Therapy (BAT)
16 Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis Completed NCT01437787 Phase 3 SAR302503;Placebo
17 High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) Completed NCT00050531 Phase 3 Gleevec;Peg-alpha interferon (Peg-Intron);Sargramostim (GM-CSF)
18 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
19 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
20 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
21 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
22 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
23 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
24 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
25 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
26 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
27 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
28 Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease Completed NCT00529568 Phase 3 eltrombopag;placebo
29 Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease Completed NCT00516321 Phase 3 eltrombopag;placebo
30 A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis Completed NCT00988221 Phase 3 Tocilizumab;Placebo
31 A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA) Completed NCT00642460 Phase 3 tocilizumab [RoActemra/Actemra];Placebo;Non-steroidal anti-inflammatory drugs (NSAIDs);methotrexate;corticosteroids
32 Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia Recruiting NCT02611973 Phase 3 Hydroxyurea treatment (HU)
33 The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line Recruiting NCT02962388 Phase 2, Phase 3 Anagrelide;Ruxolitinib (JAKAVI®);IFNα/ PegIFNα
34 A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients Recruiting NCT01621204 Phase 3 Eltrombopag;IVIG infusion
35 Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF Active, not recruiting NCT02101268 Phase 3 Momelotinib;Best Available Therapy (BAT)
36 Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis Active, not recruiting NCT01969838 Phase 3 Momelotinib;Ruxolitinib;Placebo to match momelotinib;Placebo to match ruxolitinib
37 A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms Active, not recruiting NCT01387763 Phase 3 PegIntron;Pegasys;PegIntron;Pegasys;Hydrea
38 Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence Active, not recruiting NCT01178281 Phase 3 Pomalidomide 0.5 mg;Placebo
39 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
40 Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome Not yet recruiting NCT03540810 Phase 3 Hydroxychloroquine;Placebo
41 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia Terminated NCT02055781 Phase 3 Pacritinib;Best Available Therapy
42 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Terminated NCT01773187 Phase 3 Pacritinib;Best Available Therapy
43 A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia Unknown status NCT00866762 Phase 2 HDAC inhibitor (MK-0683)
44 LBH589 (Panobinostat) for the Treatment of Myelofibrosis Unknown status NCT01298934 Phase 1, Phase 2 LBH589
45 CEP-701 (Lestaurtinib) in Myelofibrosis Unknown status NCT00668421 Phase 1, Phase 2 CEP-701 (Lestaurtinib)
46 Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis Completed NCT00586651 Phase 2 lestaurtinib
47 Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Completed NCT01259817 Phase 2 PEGASYS;Aspirin
48 Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis Completed NCT00509899 Phase 1, Phase 2 Ruxolitinib
49 The Pharmacokinetics of Anagrelide in Elderly and Young Patients With Essential Thrombocythaemia (ET) Completed NCT00413634 Phase 2 anagrelide hydrochloride
50 Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera Completed NCT01243073 Phase 2 Imetelstat

Search NIH Clinical Center for Thrombocytosis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: thrombocytosis

Sources

Genetic Tests for Thrombocytosis

About this section

Genetic tests related to Thrombocytosis:

# Genetic test Affiliating Genes
1 Thrombocytosis 29
Sources

Anatomical Context for Thrombocytosis

About this section

MalaCards organs/tissues related to Thrombocytosis:

41
Myeloid, Bone, Bone Marrow, Liver, Lung, Testes, T Cells
Sources

Publications for Thrombocytosis

About this section

Articles related to Thrombocytosis:

(show top 50) (show all 766)
# Title Authors Year
1
The course of acquired von Willebrand syndrome during pregnancy among patients with essential thrombocytosis. ( 29654448 )
2018
2
Preoperative elevated platelet count and thrombocytosis in gynecologic malignancies. ( 29404744 )
2018
3
Successful replantation of 2 digits in a patient with thrombocytosis after splenectomy: A case report. ( 29851840 )
2018
4
Preliminary investigation about the expression of tubulin in platelets from patients with iron deficiency anemia and thrombocytosis. ( 29499633 )
2018
5
Assessment of procoagulant potential in patients with reactive thrombocytosis and its association with platelet count. ( 29240268 )
2018
6
Essential thrombocytosis 40 years after splenectomy. ( 29602892 )
2018
7
A Rare Case of Pediatric Chronic Myelogenous Leukemia Presenting With Severe Thrombocytosis Without Leukocytosis. ( 29187020 )
2018
8
Factors associated with ultrasound-guided water enema reduction for pediatric intussusception in resource-limited setting: potential predictive role of thrombocytosis and anemia. ( 29459045 )
2018
9
Progression to polythythemia vera from familial thrombocytosis with germline JAK2 R867Q mutation. ( 29368262 )
2018
10
Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage. ( 29282219 )
2018
11
Transformation of MDS/MPN-RS-T to AML: Trisomy 13, resistant thrombocytosis and transient disease control with oral busulfan therapy. ( 28984013 )
2018
12
Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts. ( 29373977 )
2018
13
Germline JAK2 L611S mutation in a child with thrombocytosis. ( 29567786 )
2018
14
Plateletpheresis: Nonoperative Management of Symptomatic Carotid Thrombosis in a Patient with Reactive Thrombocytosis. ( 29555611 )
2018
15
Platelet Characteristics in Patients with Essential Thrombocytosis. ( 29790256 )
2018
16
Spurious thrombocytosis in the setting of hemolytic anemia and microcytosis secondary to extensive burn injury. ( 29391327 )
2018
17
Thrombocytosis in a male patient with acute promyelocytic leukaemia during all-trans retinoic (ATRA) acid treatment. ( 29633731 )
2018
18
Thrombocytosis in children: Clinico-hematological profile from a single centre in Eastern India. ( 29403202 )
2018
19
The pretreatment thrombocytosis as one of prognostic factors for gastric cancer: A systematic review and meta-analysis. ( 29654963 )
2018
20
Successful replantation of 2 digits in a patient with thrombocytosis after splenectomy: A case report: Erratum. ( 29979453 )
2018
21
Jak-2 mutation frequency in patients with thrombocytosis. ( 29732039 )
2018
22
Integrated micro/messenger RNA regulatory networks in essential thrombocytosis. ( 29420626 )
2018
23
Preoperative SCC-Ag and thrombocytosis as predictive markers for pelvic lymphatic metastasis of squamous cervical cancer in early FIGO stage. ( 29760805 )
2018
24
Pediatric Chronic Myeloid Leukemia Presenting With Extreme Thrombocytosis Simulating Essential Thrombocythemia. ( 29668550 )
2018
25
Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis. ( 29442537 )
2018
26
Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). ( 29067707 )
2018
27
Therapeutic Thrombocytapheresis for Symptomatic Thrombocytosis in Hemato-Oncology Patients. ( 29205870 )
2018
28
Aggregometry in the settings of thrombocytopenia, thrombocytosis and antiplatelet therapy. ( 29537938 )
2018
29
Is thrombocytosis always an indicator of autosplenectomy in patients with systemic lupus erythematosus? ( 29119304 )
2018
30
Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis. ( 28419183 )
2017
31
Carotid Artery Stiffness, Digital Endothelial Function, and Coronary Calcium in Patients with Essential Thrombocytosis, Free of Overt Atherosclerotic Disease. ( 28740456 )
2017
32
Preoperative thrombocytosis as a prognostic factor in endometrioid-type endometrial carcinoma. ( 28988254 )
2017
33
Acute renal infarction: a presentation of essential thrombocytosis. ( 29055434 )
2017
34
Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma. ( 28694147 )
2017
35
Refractory anemia with ring sideroblasts and thrombocytosis. ( 28401094 )
2017
36
Ertapenem-Induced Thrombocytosis. ( 28652947 )
2017
37
Acute myeloid leukemia with mutated NPM1 demonstrating multilineage dysplasia and marked thrombocytosis. ( 28677819 )
2017
38
The Significance of Pretreatment Thrombocytosis and Its Association With Neutrophilia in Patients With Surgically Treated Endometrial Cancer. ( 28604454 )
2017
39
Clinical and laboratory assessment of a patient with thrombocytosis. ( 29019736 )
2017
40
Cyclic thrombocytopenia synchronizing with the menstrual cycle showing periodic phases of thrombocytopenia and rebound thrombocytosis. ( 28413179 )
2017
41
The role of certain gene polymorphisms involved in the apoptotic pathways in polycythemia vera and essential thrombocytosis. ( 29068570 )
2017
42
Magnitude of reactive thrombocytosis and associated clinical conditions in dogs. ( 28780529 )
2017
43
Extending Carotid Artery Thrombus Associated with Thrombocytosis. ( 29279468 )
2017
44
Management of extreme thrombocytosis in myeloproliferative neoplasms: an international physician survey. ( 27734130 )
2017
45
A Violaceous, Photodistributed Cutaneous Eruption and Leg Ulcer in a Woman With Essential Thrombocytosis. ( 28877306 )
2017
46
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management. ( 28188970 )
2017
47
Isolated thrombocytosis in chronic myeloid leukemia without significant leukocytosis. ( 28781272 )
2017
48
Paraneoplastic thrombocytosis is associated with increased mortality and increased rate of lymph node metastasis in oesophageal adenocarcinoma. ( 28668174 )
2017
49
The clinicopathological and prognostic role of thrombocytosis in patients with cancer: A meta-analysis. ( 28588739 )
2017
50
Thrombocytosis in gynecological cancers. ( 28643732 )
2017
Sources

Variations for Thrombocytosis

About this section
Sources

Expression for Thrombocytosis

About this section
Search GEO for disease gene expression data for Thrombocytosis.
Sources

Pathways for Thrombocytosis

About this section

Pathways related to Thrombocytosis according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
PEDF Induced Signaling 64
Show member pathways
 13.45 CSF2 EPO F2 IL11 IL3 IL6
2
TGF-Beta Pathway 64
Show member pathways
 13.27 EPO F2 IL11 IL3 IL6 JAK2
3
Akt Signaling 64
Show member pathways
 13.23 CSF2 IL11 IL3 IL6 JAK2 THPO
4
PAK Pathway 64
Show member pathways
 13.12 CSF2 IL11 IL3 IL6 JAK2 THPO
5
Response to elevated platelet cytosolic Ca2+ 66
Show member pathways
 13.05 CSF2 F2 F3 IL3 JAK2 MPL
6
p70S6K Signaling 64
Show member pathways
 12.87 F2 IL3 IL6 JAK2 THPO
7
Regulation of IFNA signaling 66
Show member pathways
 12.15 CSF2 EPO IL11 IL3 IL6 JAK2
8
G beta-gamma signalling through PI3Kgamma 66
Show member pathways
 11.98 CSF2 IL3 JAK2
9
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.93 IL11 IL3 IL6 JAK2 THPO
10
Complement and coagulation cascades 1 37
11.92 F2 F3 SERPINC1
11
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.92 IL11 IL3 IL6 THPO
12
AGE-RAGE signaling pathway in diabetic complications 37
11.76 F3 IL6 JAK2
13
Jak-Stat Signaling Pathway 67
11.76 EPO IL3 IL6 JAK2
14
Visual Cycle in Retinal Rods 64
11.75 CRP JAK2 MPL THPO
15
Integrin alphaIIb beta3 signaling 66
Show member pathways
 11.73 F2 MPL THPO
16
Cytokine production by Th17 cells in CF (Mouse model) 22
Show member pathways
 11.7 CSF2 IL6 JAK2
17
Rheumatoid arthritis 37
11.68 CSF2 IL11 IL6
18
IL6-mediated signaling events 1
Show member pathways
 11.65 CRP IL6 JAK2
19
Hematopoietic cell lineage 37
11.62 CSF2 EPO IL11 IL3 IL6 THPO
20
Differentiation Pathway 1
11.39 EPO IL11 IL3 IL6
21
Hematopoietic Stem Cell Differentiation 1
11.35 CSF2 EPO IL3 IL6
22
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.23 CSF2 EPO IL11 IL3 IL6 MPL
23
Cytokines and Inflammatory Response 1
11.03 CSF2 IL11 IL3 IL6
24
Overview of nanoparticle effects 1
10.88 CRP IL6
Sources

GO Terms for Thrombocytosis

About this section

Cellular components related to Thrombocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CRP CSF2 EPO F2 F3 IL11
2 extracellular space GO:0005615 9.36 CRP CSF2 EPO F2 F3 IL11

Biological processes related to Thrombocytosis according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.87 CSF2 EPO F2 IL11 IL3 IL6
2 blood coagulation GO:0007596 9.76 F2 F3 JAK2 SERPINC1
3 regulation of signaling receptor activity GO:0010469 9.7 CSF2 EPO F2 IL11 IL3 IL6
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.67 F2 JAK2 SELP
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.67 IL11 IL3 IL6 JAK2
6 hemostasis GO:0007599 9.65 F2 F3 SERPINC1
7 positive regulation of DNA replication GO:0045740 9.61 CSF2 EPO IL3
8 acute-phase response GO:0006953 9.56 CRP EPO F2 IL6
9 myeloid cell differentiation GO:0030099 9.55 TET2 THPO
10 interleukin-6-mediated signaling pathway GO:0070102 9.54 IL6 JAK2
11 regulation of blood coagulation GO:0030193 9.52 F2 SERPINC1
12 negative regulation of lipid storage GO:0010888 9.51 CRP IL6
13 thrombopoietin-mediated signaling pathway GO:0038163 9.4 MPL THPO
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.35 CSF2 EPO IL3 IL6 JAK2
15 cytokine-mediated signaling pathway GO:0019221 9.17 CSF2 F3 IL11 IL3 IL6 JAK2

Molecular functions related to Thrombocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.43 CSF2 EPO IL11 IL3 IL6 THPO
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.33 CSF2 IL3 JAK2
3 growth factor activity GO:0008083 9.1 CSF2 F2 IL11 IL3 IL6 THPO
Sources

Sources for Thrombocytosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....